Sandra J. Lee

6.5k total citations · 2 hit papers
98 papers, 3.4k citations indexed

About

Sandra J. Lee is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Sandra J. Lee has authored 98 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Oncology, 28 papers in Molecular Biology and 20 papers in Immunology. Recurrent topics in Sandra J. Lee's work include Cutaneous Melanoma Detection and Management (22 papers), Global Cancer Incidence and Screening (22 papers) and Melanoma and MAPK Pathways (17 papers). Sandra J. Lee is often cited by papers focused on Cutaneous Melanoma Detection and Management (22 papers), Global Cancer Incidence and Screening (22 papers) and Melanoma and MAPK Pathways (17 papers). Sandra J. Lee collaborates with scholars based in United States, Netherlands and Canada. Sandra J. Lee's co-authors include John M. Kirkwood, Marvin Zelen, Judy Lieberman, Deborah Palliser, Vernon K. Sondak, David M. Knipe, Roderick T. Bronson, Dipanjan Chowdhury, Qing-Yin Wang and Michael B. Atkins and has published in prestigious journals such as Nature, JAMA and Journal of Clinical Oncology.

In The Last Decade

Sandra J. Lee

93 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

2008 534 citations Sandra J. Lee, Vernon K. Sondak et al. Journal of Clinical Oncology profile →
Analysis of Breast Cancer Mortality in the US—1975 to 2019

2024 89 citations John M. Hampton, Jinani Jayasekera et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sandra J. Lee United States	29	1.8k	1.2k	650	505	320	98	3.4k
Antonio Martı́nez Spain	45	2.8k 1.6×	1.5k 1.2×	1.4k 2.1×	891 1.8×	592 1.9×	157	6.7k
Rachel Humphrey United States	23	4.2k 2.4×	1.0k 0.9×	2.1k 3.2×	607 1.2×	346 1.1×	50	5.3k
Andrew L. Pecora United States	26	1.2k 0.7×	680 0.6×	901 1.4×	353 0.7×	402 1.3×	131	3.3k
Don Morris Canada	30	1.1k 0.6×	1.4k 1.1×	305 0.5×	241 0.5×	208 0.7×	91	3.3k
Kishor Bhatia United States	43	3.8k 2.1×	2.1k 1.7×	962 1.5×	682 1.4×	653 2.0×	156	6.1k
Chunqiao Tian United States	34	1.2k 0.7×	840 0.7×	207 0.3×	455 0.9×	555 1.7×	107	4.1k
Go Kimura Japan	25	550 0.3×	573 0.5×	321 0.5×	285 0.6×	238 0.7×	167	2.4k
A. Dupuy France	31	916 0.5×	694 0.6×	501 0.8×	201 0.4×	693 2.2×	133	3.4k
Alfons J.M. van den Eertwegh Netherlands	44	2.4k 1.4×	1.3k 1.1×	3.7k 5.6×	493 1.0×	429 1.3×	152	6.0k
Susan E. Krown United States	43	3.7k 2.1×	1.2k 1.0×	1.3k 2.0×	315 0.6×	1.3k 4.0×	129	6.2k

Countries citing papers authored by Sandra J. Lee

Since Specialization

Citations

This map shows the geographic impact of Sandra J. Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra J. Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra J. Lee more than expected).

Fields of papers citing papers by Sandra J. Lee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra J. Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra J. Lee. The network helps show where Sandra J. Lee may publish in the future.

Co-authorship network of co-authors of Sandra J. Lee

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra J. Lee. A scholar is included among the top collaborators of Sandra J. Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra J. Lee. Sandra J. Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tarhini, Ahmad A., Sandra J. Lee, William A. LaFramboise, et al.. (2025). Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma. Clinical Cancer Research. 31(15). 3249–3258.

Mandelblatt, Jeanne S., Clyde B. Schechter, Natasha K. Stout, et al.. (2023). Population simulation modeling of disparities in US breast cancer mortality. JNCI Monographs. 2023(62). 178–187. 4 indexed citations

Li, Xiaoyu, Yue Zheng, Sandra J. Lee, et al.. (2023). Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade. Cancer Immunology Research. 11(8). 1100–1113. 3 indexed citations

Alagöz, Oğuzhan, Kathryn P. Lowry, Allison W. Kurian, et al.. (2021). Impact of the COVID-19 Pandemic on Breast Cancer Mortality in the US: Estimates From Collaborative Simulation Modeling. JNCI Journal of the National Cancer Institute. 113(11). 1484–1494. 100 indexed citations

Trentham‐Dietz, Amy, Oğuzhan Alagöz, Christina Chapman, et al.. (2021). Reflecting on 20 years of breast cancer modeling in CISNET: Recommendations for future cancer systems modeling efforts. PLoS Computational Biology. 17(6). e1009020–e1009020. 10 indexed citations

Najjar, Yana G., Mäneka Puligandla, Sandra J. Lee, & John M. Kirkwood. (2019). An updated analysis of 4 randomized ECOG trials of high‐dose interferon in the adjuvant treatment of melanoma. Cancer. 125(17). 3013–3024. 12 indexed citations

Tarhini, Ahmad A., Sandra J. Lee, Xiaoxue Li, et al.. (2018). E3611—A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma. Clinical Cancer Research. 25(2). 524–532. 6 indexed citations

Ryser, Marc D., Donald L. Weaver, Fengmin Zhao, et al.. (2018). Cancer Outcomes in DCIS Patients Without Locoregional Treatment. JNCI Journal of the National Cancer Institute. 111(9). 952–960. 85 indexed citations

Wilson, Melissa, Fengmin Zhao, Sanika Khare, et al.. (2015). Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clinical Cancer Research. 22(2). 374–382. 31 indexed citations

10.

Wilson, Melissa, Fengmin Zhao, Richard Letrero, et al.. (2014). Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib. Clinical Cancer Research. 20(12). 3328–3337. 30 indexed citations

11.

Go, Ronald S., Sandra J. Lee, Donghoon Shin, et al.. (2013). ECOG Phase II Trial of Graded-Dose Peginterferon α-2b in Patients with Metastatic Melanoma Overexpressing Basic Fibroblast Growth Factor (E2602). Clinical Cancer Research. 19(23). 6597–6604. 7 indexed citations

12.

Siddappa, Nagadenahalli B., Victor G. Kramer, Sandra J. Lee, et al.. (2013). Live Attenuated Rev-Independent Nef¯SIV Enhances Acquisition of Heterologous SIVsmE660 in Acutely Vaccinated Rhesus Macaques. PLoS ONE. 8(9). e75556–e75556. 7 indexed citations

13.

Flaherty, Keith T., Sandra J. Lee, Fengmin Zhao, et al.. (2012). Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma. Journal of Clinical Oncology. 31(3). 373–379. 160 indexed citations

14.

Ravesteyn, Nicolien T. van, Diana L. Miglioretti, Natasha K. Stout, et al.. (2012). Tipping the Balance of Benefits and Harms to Favor Screening Mammography Starting at Age 40 Years. Obstetrical & Gynecological Survey. 67(8). 481–482. 1 indexed citations

15.

Siddappa, Nagadenahalli B., et al.. (2011). Schistosoma mansoni Enhances Host Susceptibility to Mucosal but Not Intravenous Challenge by R5 Clade C SHIV. PLoS neglected tropical diseases. 5(8). e1270–e1270. 25 indexed citations

16.

Jilaveanu, Lucia B., Christopher R. Zito, Sandra J. Lee, et al.. (2009). Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib. Clinical Cancer Research. 15(3). 1076–1085. 33 indexed citations

17.

Lee, Sandra J. & Marvin Zelen. (2007). Mortality Modeling of Early Detection Programs. Biometrics. 64(2). 386–395. 17 indexed citations

18.

Palliser, Deborah, Dipanjan Chowdhury, Qing-Yin Wang, et al.. (2005). An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature. 439(7072). 89–94. 317 indexed citations

19.

Lange, Christoph, Zhan Xu, Bruce K. Patterson, et al.. (2004). Proliferation responses to HIVp24 during antiretroviral therapy do not reflect improved immune phenotype or function. AIDS. 18(4). 605–613. 13 indexed citations

20.

Zelen, Marvin & Sandra J. Lee. (2002). Models and the Early Detection of Disease: Methodological Considerations. Cancer treatment and research. 113. 1–18. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact